Indication (pathologie):
Keratosis
Identifiant SNOMED-CT:
SCTID 254666005
Etudes cliniques
-
Observation imagée de l’utilisation du CryopenIndication (pathologie):CondylomaIdentifiant SNOMED-CT:SCTID 19672005Recrutement: Ouvert
-
A multi-center, randomized, double-blind, active and placebo-controlled study to investigate the efficacy and safety of ligelizumab (QGE031) in the treatment of chronic spontaneous urticaria (CSU) in adolescents and adults inadequately controlled with H1-antihistaminesIndication (pathologie):Chronic urticariaIdentifiant SNOMED-CT:SCTID 51611005Phase de l'étude: Phase IIIRecrutement: Ouvert
-
A phase 2 multicenter, investigator-blind, subject-blind, placebo-controlled study of the efficacy, safety, and pharmacokinetics of bimekizumab in subjects with moderate to severe hidradenitis suppurativaIndication (pathologie):Hidradenitis suppurativaIdentifiant SNOMED-CT:SCTID 59393003Phase de l'étude: Phase IIRecrutement: Ouvert
-
The occurrence of childhood and lifetime traumatic events among adults with Hidradenitis suppurativa: a case control studyIndication (pathologie):Hidradenitis suppurativaIdentifiant SNOMED-CT:SCTID 59393003Recrutement: Ouvert
-
Observation imagée de l’utilisation du CryopenIndication (pathologie):KeratosisIdentifiant SNOMED-CT:254666005Indication (pathologie):Condyloma acuminataIdentifiant SNOMED-CT:237110007Recrutement: Ouvert
-
A multi-center, randomized, double-blind, active and placebo-controlled study to investigate the efficacy and safety of ligelizumab (QGE031) in the treatment of Chronic Spontaneous Urticaria (CSU) in adolescents and adults inadequately controlled with H1-antihistaminesIndication (pathologie):Chronic urticariaIdentifiant SNOMED-CT:51611005Phase de l'étude: Phase IIIRecrutement: Ouvert
-
A multicenter, randomized, double-blind, secukinumab-controlled, parallel-group study to evaluate the efficacy and safety of bimekizumab in adult subjects with moderate to severe chronic plaque psoriasisIndication (pathologie):Chronic large plaque psoriasisIdentifiant SNOMED-CT:402307000Indication (pathologie):Chronic small plaque psoriasisIdentifiant SNOMED-CT:402308005Phase de l'étude: Phase IIIRecrutement: Ouvert
-
A phase 2 Multicenter, Investigator-blind, Subject-blind, Placebo-controlled study of the Efficacy, Safety, and Pharmacokinetics of Bimekizumab in Subjects with Moderate to Severe Hidradenitis SuppurativaIndication (pathologie):Hidranitis suppurativaIdentifiant SNOMED-CT:59393003Phase de l'étude: Phase IIRecrutement: Ouvert
-
The occurrence of childhood and lifetime traumatic events among adults with Hidradenitis suppurativa: a case control studyIndication (pathologie):Hidranitis suppurativaIdentifiant SNOMED-CT:59393003Recrutement: Ouvert
-
« Long term observational, prospective study to collect in a real-life setting data on the retention, effectiveness, safety, treatment pattern, quality of life (QoL), and efficiency of secukinumab in adult patients with moderate to severe plaque psoriasis. ».Indication (pathologie):PsoriasisIdentifiant SNOMED-CT:SNOMEDCT/9014002Recrutement: Fermé
-
Effectiveness of adalimumab in moderate to severe HidrAdenitis suppuRativa patients. A Multi cOuNtrY study in real life setting (HARMONY)Indication (pathologie):Maladie de VerneuilIdentifiant SNOMED-CT:59393003Phase de l'étude: Phase IVRecrutement: Fermé
-
An observational study of the real-life management of psoriasis patients treated with OTEZLA® (apremilast) in BelgiumIndication (pathologie):PsoriasisIdentifiant SNOMED-CT:9014002Phase de l'étude: Phase IVRecrutement: Ouvert
-
A phase 2 multicenter, investigator-blind, subject-blind, placebo-controlled study of the efficacy, safety, and pharmacokinetics of bimekizumab in subjects with moderate to severe hidradenitis suppurativaIndication (pathologie):Maladie de VerneuilIdentifiant SNOMED-CT:59393003Phase de l'étude: Phase IIRecrutement: Ouvert
-
A multicenter, open Label study to assess the safety and efficacy of rIsankizuMab for MaInTenance in moderate to severe pLaquE type pSoriaSis (LIMMITLESS)Indication (pathologie):PsoriasisIdentifiant SNOMED-CT:9014002Phase de l'étude: Phase IIIRecrutement: Fermé
-
A phase 4, double-blind, randomized, placebo-controlled multicenter study to assess the safety and efficacy of Adalimumab used in conjunction with surgery in subjects with moderate to severe hidradenitis suppurativaIndication (pathologie):Maladie de VerneuilIdentifiant SNOMED-CT:59393003Phase de l'étude: Phase IVRecrutement: Ouvert